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INTRODUCTION:  Non-Hodgkin  lymphoma  (NHL)  can  occur  at any  site  of  the  body,  however  diffuse  and
extensive  involvement  of the peritoneal  cavity  occurs  rarely.  Diffuse  large B-cell  lymphoma  (DLBCL)
is  one  of the  dominant  histological  subtypes  in  extra  nodal  lymphoma  involving  the  peritoneal  cavity
while  Burkitt  lymphoma  is seen  less  commonly.  We  report  two cases  of  DLBCL  and  one  case  of Burkitt
lymphoma  presenting  with peritoneal  lymphomatosis  (PL).
PRESENTATION  OF  CASE:  A  retrospective  review  of  two cases  involving  DLBCL  and  one  case  of  Burkitt
lymphoma  with  PL  was  conducted.  Findings  in  all patients  were  consistent  with peritoneal  carcinomatosis
at  initial  evaluation.  Symptoms  included  longstanding  vague  abdominal  pain  and  weight  loss.  CT  imaging
along  with  biopsies  showed  DLBCL  in two  cases  and  Burkitt  lymphoma  in  one  case.  All  three  patients  were
treated  with  chemotherapy  and  responded  very  well.
DISCUSSION:  We  report  three  cases  of non-Hodgkin  lymphoma  presenting  with  peritoneal  lymphomato-
sis,  a  rare  phenomena.  Due  to its nonspeciﬁc  presentation,  laparoscopic  biopsies  with  subsequent
pathology  analysis  should  be undertaken  as  quickly  and  efﬁciently  as  possible  to  accurate  diagnose  and
treat  this  condition.
CONCLUSION:  DLBCL  with  PL  may  have  variable  and  non-speciﬁc  presentations.  It may  resemble  peri-
toneal  carcinomatosis  or  other  neoplastic  and inﬂammatory  conditions.  Focused  clinical  awareness,
high  level  of  suspicion,  and complementary  approach  can lead towards  accurate  diagnosis.  Diagnostic
laparoscopy  plays  a crucial  role  in facilitating  diagnosis  and  treatment.
© 2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
In the United States, the incidence rate of non-Hodgkin lym-
homa (NHL) for adults was  19.7 per 100,000 per year with a total of
49,625 patients living with NHL [1]. The gastrointestinal (GI) tract
s the most common extranodal organ system that is affected [2,3],
owever involvement of the peritoneum occurs only very rarely
4,5]. Of the 60 subtypes of NHL [6], diffuse large B-cell lymphoma
DLBCL) is the most common [7,8] with Burkitt lymphoma present-
ng as one of the least common [1]. DLBCL is predominantly seen
s one ages [7,9] with the majority of individuals being diagnosed
etween ages 50–70 [1]. Like in DLBCL, Burkitt lymphoma has a
igher predilection for males than females but a bimodal age of
istribution is seen with an initial peak in the adolescent years and
he subsequent peak in middle adulthood [7,9]. Both of these sub-
ypes of NHL present with similar symptoms such as abdominal
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pain, fever, fatigue, night sweats, and weight loss. These symptoms
are nonspeciﬁc as they may  also occur in various other cancers
as well as in nonmalignant infectious or inﬂammatory conditions.
Appropriate workup is thus necessary to facilitate quick and efﬁ-
cient diagnosis of the presenting patient and to effectively manage
and treat the condition.(Figs 1–3)
2. Presentation of case
Case #1: A 29-year-old male presented with nausea, vomiting,
diarrhea, abdominal pain localized in the upper abdomen, weight
loss of 10–15 pounds within the three weeks of presentation, and
increased sweating particularly in the evenings, which were all pre-
ceded by diplopia. Vitals were within normal physiological limits
except for an O2 saturation of 92%. Abdominal examination showed
epigastric tenderness with moderated abdominal distension and
occasional high-pitched bowel sounds. Decreased inward gaze of
the left eye along with miosis was noted. The remainder of the
physical exam was normal along with laboratory values except for
a white blood cell count of 12,800/mm3 and a platelet count of
582,000/mm3. CT imaging of the abdomen and pelvis showed irreg-
ular thickening of the gastric wall with involvement of the body
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Arrows showing omental caking with hemorrhage in case 1.
Fig. 2. Arrows showing peritoneal nodules in case 1.
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Rig. 3. Arrows showing extensive inﬁltrate and nodules within the peritoneum and
mentum in case 2.
nd antrum, an exophytic mass at the gastric fundus, and exten-
ive nodularity on the omentum. An esophagogastroduodenoscopy
EGD) showed an ulcerative tumor at the distal stomach. Subse-
uent biopsy undertaken showed high-grade malignant B-cell NHL
 DLBCL or Burkitt lymphoma. Immunohistochemistry staining
howed: pankeratin-, CD20+, CD10+, MUM1+, BCL6+, BCL2-, CD3+,
D5+, EBER ISH-, and Ki67 near 100%. Laparoscopy with biopsy con-
ucted veriﬁed c-MYC translocation conﬁrming Burkitt lymphoma.
ther procedures included a CT guided bone marrow biopsy and X-
ay (XR) guided spinal tap that were negative for malignancy, andPEN  ACCESS
ery Case Reports 28 (2016) 262–265 263
a magnetic resonance imaging (MRI) of the brain and a whole body
PET scan showed no abnormalities.
Case # 2: A 46-year-old male presented with abdominal pain
localized in his left lower quadrant (LLQ) of ten days duration
and weight loss of 100 pounds for the past nine months. On
examination the patient was in mild distress with mild tender-
ness on the LLQ and dyspnea at times. Laboratory examination
was within normal limits. CT imaging of the abdomen and pelvis
was suggestive for diffuse peritoneal involvement with subsequent
CT guided core needle biopsy conﬁrming DLBC—germinal type.
Immunohistochemistry staining showed: GCET1+, FOXP1+, CD10+,
CD20+, BCL6+, BCL2-, CD3- pankeratin-, MUM1-, and EBER ISH-. A
CT guided thoracentesis was conducted for dyspnea due to pleu-
ral effusion. The cytology showed few atypical cells and reactive
mesothelial cells.
Case # 3: A 67-year-old female presented with severe abdom-
inal pain localized in the LLQ, bloating, distension, ﬂank pain,
unintentional weight loss, nausea, vomiting, diarrhea, fatigue, and
decreased appetite. Physical exam showed diffuse tenderness in the
LLQ, a ﬂuid thrill/shifting dullness, and palpable irregular nodular-
ities localized in the LLQ. CT of the abdomen and pelvis showed
diffuse omental and mesenteric carcinomatosis with metastatic
implants extending into the posterior mediastinum via diaphrag-
matic hiatus, and an irregular satellite mass of 7.9 cm.  A CT guided
core biopsy showed malignancy consistent with DLBCL − germinal
type. Subsequent XR spinal tap with cerebrospinal ﬂuid cytology
times two  showed no evidence of malignancy.
All three patients were started on Rituximab, Cyclophos-
phamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
therapy, the standard of care for DLBCL. Methotrexate and Cytara-
bine administration was interspersed throughout these cycles. In
the end, the patient in case two  and three received a total of
eight cycles of treatment. In case one, the patient received an
initial single treatment dose of R-CHOP therapy. After conﬁrma-
tion of Burkitt lymphoma, the patient was  switched to Rituximab
− hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin,
and Dexamethasone with alternating Methotrexate and Cytarabine
(R-HCVAD/MA). A total of 4 cycles was administered for this patient.
During treatment, patients encountered mild side effects from
the drugs such as nausea, vomiting, and fatigue. Abdominal
symptoms in all three cases subsided, no resistance to the
chemotherapeutic regimen was reported, and no other major
side effects were noted. All patients completed treatment with
documentation of complete regression of disease along with
improvement of quality of life.
3. Discussion
PL, a form of extranodal lymphoma, is a rare condition that
mimics peritoneal carcinomatosis but occurs less frequently [10].
Extranodal lymphoma has an incidence of approximately 40% of
patients with lymphoma and can occur in any site of the body.
However, involvement of the peritoneal cavity is exceedingly rare
[10,11]. Extranodal lymphoma is generally a poor prognostic factor
and more common with intermediate- to high-grade NHL [10,11].
PL from secondary involvement of visceral lymphoma occurs more
frequently than primary lymphoma of the peritoneum [12]. The GI
tract accounts for 5–20% of all lymphoma cases [10] and 10–30% of
NHL patients [11]. DLBCL is the dominant subtype of NHL present-
ing as extranodal lymphoma and thus the most commonly reported
with PL [10,11]. On the other hand, Burkitt lymphoma is a rare sub-
type with conservative estimates accounting for less than 1–2% of
all NHL [8].
The omentum is not commonly involved with lymphoma
because it does not contain lymphoid tissue [11,13]. Therefore,
CASE  REPORT  –  OPEN  ACCESS
264 E. Flores et al. / International Journal of Surgery Case Reports 28 (2016) 262–265
Table 1
Table of timeline for presentation and intervention for each case.
Timeline for Presentation and Intervention
Case #: Date: Description:
1 08/10/2015 Patient presented with symptoms of nausea, vomiting, diarrhea, abdominal pain, sweating, and weight loss to his general practitioner.
08/28/2015 CT imaging of the abdomen and pelvis showed irregular thickening of the gastric wall and extensive nodularity on the omentum.
08/29/2015 High-grade malignant B-cell NHL − DLBCL or Burkitt lymphoma conﬁrmed via EGD.
09/01/2015 Laparoscopy with biopsy conducted.
09/03/2015 R-CHOP therapy started.
Week of
09/24/2015
Conﬁrmation of Burkitt lymphoma.
09/28/2015 R-CHOP therapy discontinued; Hyper-CVAD/MA therapy started.
2 10/18/2015 Patient presented with symptoms of abdominal pain and weight loss. CT imaging of the abdomen and pelvis suggested diffuse peritoneal
metastatic disease.
10/20/2015 CT guided biopsy was consistent with diffuse large B-cell lymphoma.
10/28/2015 R-CHOP therapy started.
3 August 2015 Patient presented with symptoms of abdominal pain, weight loss, nausea, vomiting, and diarrhea.
08/22/2015 CT imaging of the abdomen and pelvis showed probable omental and mesenteric carcinomatosis with metastatic implants.
09/08/2015 CT guided biopsy consistent with diffuse large B-cell lymphoma.
09/16/2015 R-CHOP therapy started.
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ihe route of dissemination is unclear although propagation is
resumed to occur via pathways like the visceral peritoneal sur-
aces, gastrocolic ligament, and transverse mesocolon [10,11,13].
n contrast, dissemination to the omentum commonly occurs from
etastatic carcinoma of the ovary, colon, and stomach [11]. Three
ell lines may  affect the peritoneal surface from secondary malig-
ancies: epithelial (carcinomatosis), mesenchymal (sarcomatosis),
nd lymphoid (lymphomatosis) [11]. In contrast to peritoneal car-
inomatosis, treatment of PL is usually by chemotherapy versus
urgery [14]. Unless there is a complication of lymphoma, surgery
hould be the last resort.(Table 1)
Our patients presented clinically with vague abdominal discom-
ort that included pain and swelling. The imaging studies between
he cases showed similarities as well. Typical CT ﬁndings of PL
nclude omental caking with peritoneal enhancement, thicken-
ng, and nodularity with ascites, which are indistinguishable from
eritoneal carcinomatosis [12]. However, there are other signs on
T that may  help differentiate PL from peritoneal carcinomatosis:
ymph node involvement, splenomegaly, and tumors in GI tract
14]. Deﬁnitive diagnosis can only be made through histological
onﬁrmation [12].
In the literature it has been shown that there is an established
elationship between lymphoma and speciﬁc markers. There are
aboratory techniques such as immunohistochemistry that can be
mployed to help identify the type of neoplasm. Once proper iden-
iﬁcation is complete, medications can be tailored toward that
peciﬁc subtype. There are various markers throughout the B-cell
ifecycle that can be speciﬁcally stained to provide conﬁrmation.
n Burkitt lymphoma and DLBCL, staining of markers within the
-cell lineage is useful in this endeavor. Of the series of markers
tained in case one, CD20 is of clinical signiﬁcance since it is of
-cell origin [15,16]. The remaining markers can have positivity
n both T-cells and B-cells producing some confusion whilst nar-
owing the differential diagnosis. The translocation gene marker
-MYC is also very helpful in that it is seen in about 90% of cases
f Burkitt lymphoma [15]. In case two, CD20 positivity was present
long with other helpful markers that not only conﬁrmed a neo-
lasm of B-cells but also categorized it as germinal center subtype
MUM1  negative and GCET1 positive), which is seen with DLBCL
16]. Although these markers assist us in developing a diagno-
is, diagnostic conﬁrmation is done through the combination of
ymptoms on presentation, physical examination, imaging studies,
mmunohistochemistry staining, and histological reports.4. Conclusion
PL usually manifests as aggressive histological subtypes of high-
grade lymphomas that lead to rapid progression and deterioration.
It is therefore crucial to be aware of this rare entity to provide
early diagnosis and optimal treatment that may  prolong life. It has
been reported that cytology has been used as an invaluable method
to establish a diagnosis of PL from ascites with time limitation
[10,5]. However, cases with inconclusive cytology require laparo-
scopic or image-guided needle biopsy for a deﬁnitive diagnosis. If
image guided biopsy is unavailable or inconclusive laparoscopy is
recommended. It is important to note that unless there is a com-
plication of lymphoma, surgery should be refrained as it may  lead
to progression and deterioration [10].
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